NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Lantern Pharma's LP-184 Phase 1a Results and AI-Driven Oncology Pipeline
TL;DR
Lantern Pharma's LP-184 drug shows promising results with a potential $10 billion market opportunity, offering investors a competitive edge in oncology innovation.
Lantern Pharma's Phase 1a study established a recommended Phase 2 dose for LP-184 using AI-driven biomarker analysis across multiple cancer types.
This AI-powered oncology research accelerates life-changing therapies for hundreds of thousands of cancer patients worldwide, improving treatment outcomes.
Lantern Pharma's AI platform analyzes 200 billion data points to develop cancer drugs, demonstrating how technology revolutionizes medical research.
Found this article helpful?
Share it with your network and spread the knowledge!
Lantern Pharma (NASDAQ: LTRN) is a clinical-stage biotechnology company that uses artificial intelligence (AI), machine learning (ML), and genomics to transform oncology drug development, accelerating the discovery and development of cancer therapies through its proprietary RADR® platform.
The Phase 1a dose-escalation study of LP-184 in 63 heavily pre-treated patients with advanced solid tumors met all primary endpoints for safety and tolerability, established a clear recommended Phase 2 dose, and showed encouraging signals of durable disease control, particularly in tumors with DNA damage repair pathway deficiencies.
Lantern Pharma is advancing multiple biomarker-guided Phase 1b/2 trials for LP-184 across triple-negative breast cancer, glioblastoma multiforme, non-small cell lung cancer, and advanced urothelial carcinoma.
Lantern Pharma and independent analysts estimate that LP-184's aggregate market opportunity could exceed $10 billion annually.
RADR® is Lantern Pharma's proprietary AI and machine learning platform that leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve problems in oncology drug development, accelerating the development of their therapy pipeline.
Lantern Pharma's AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD.
Lantern Pharma's growing pipeline includes therapies that span multiple cancer indications, including both solid tumors and blood cancers, as well as an antibody-drug conjugate (ADC) program.
The latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN.
BioMedWire is a specialized communications platform focused on the latest developments in Biotechnology, Biomedical Sciences, and Life Sciences sectors, and it is part of the Dynamic Brand Portfolio within IBN that distributes content through various wire solutions and syndication networks.
Curated from InvestorBrandNetwork (IBN)
